PMS-AMCLAV-200 28.5 MG / 5 ML
CLAVULANIC ACID (CLAVULANATE POTASSIUM) : 28.5 MG / 5 ML AMOXICILLIN (AMOXICILLIN TRIHYDRATE) : 200 MG / 5 ML · DIN 02241001 · PHARMASCIENCE INC
Health Canada status: CANCELLED PRE MARKET
What is PMS-AMCLAV-200?
PMS-AMCLAV-200 28.5 MG / 5 ML contains CLAVULANIC ACID (CLAVULANATE POTASSIUM) : 28.5 MG / 5 ML AMOXICILLIN (AMOXICILLIN TRIHYDRATE) : 200 MG / 5 ML. It is listed in the Health Canada Drug Product Database under DIN 02241001, held by PHARMASCIENCE INC, supplied as POWDER FOR SOLUTION for ORAL administration. Health Canada currently lists it as cancelled pre market, status dated 03-Aug-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is PMS-AMCLAV-200 called?
The same molecule, AMOXICILLIN AND BETA-LACTAMASE INHIBITOR, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| AUGMENTIN | Latin | Bahrain, Czechia |
| Amoxil | Latin | Australia, Bahrain |
| APO-Amoxycillin | Latin | Australia |
| Amoxycillin Sandoz | Latin | Australia |
| Omacillin | Latin | Bahrain, Saudi Arabia |
| Amimox® | Latin | Sweden |
| Betaklav | Latin | Czechia, Sweden |
| KLAVOX | Latin | Bahrain |
| AMILOXYN | Latin | Australia |
| APX-Amoxicillin/Clavulanic Acid | Latin | Australia |
| Cilamox | Latin | Australia |
| COMOX | Latin | Australia |
| Curam | Latin | Australia, Bahrain |
| AMOXICILLIN-WGR | Latin | Australia |
| MOXICLAV | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02241001 |
|---|---|
| Brand name | PMS-AMCLAV-200 |
| Generic / active ingredient | CLAVULANIC ACID (CLAVULANATE POTASSIUM) : 28.5 MG / 5 ML AMOXICILLIN (AMOXICILLIN TRIHYDRATE) : 200 MG / 5 ML |
| Manufacturer | PHARMASCIENCE INC |
| Strength | 28.5 MG / 5 ML |
| Dosage form | POWDER FOR SOLUTION |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR |
| AHFS class | 08:12.16.08 |
| Biosimilar | No |
| Health Canada status | CANCELLED PRE MARKET |
| Status date | 03-Aug-2017 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02241001 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2241001 |
| Brand name | PMS-AMCLAV-200 |
| Active ingredient / INN | CLAVULANIC ACID (CLAVULANATE POTASSIUM) : 28.5 MG / 5 ML AMOXICILLIN (AMOXICILLIN TRIHYDRATE) : 200 MG / 5 ML |
| ATC code | J01CR02 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01 |
| AHFS class | 08:12.16.08 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | PHARMASCIENCE INC |
Which pack is which?
| Strength on the label | 28.5 MG / 5 ML |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | ORAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Is AMOXICILLIN AND BETA-LACTAMASE INHIBITOR in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code J01CR02 AMOXICILLIN AND BETA-LACTAMASE INHIBITOR. 28 of 59 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-AMOXI CLAV | 500 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02510634 |
| AG-AMOXI CLAV | 875 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02510642 |
| AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION | 100 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02495910 |
| AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION | 1000 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02495929 |
| AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION | 2000 MG | POWDER FOR SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02495937 |
| AMOXICILLIN/CLAV | 500 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02536021 |
| AMOXICILLIN/CLAV | 875 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02536048 |
| APO-AMOXI CLAV | 125 MG | TABLET | APOTEX INC | MARKETED | DIN 02243350 |
| APO-AMOXI CLAV | 500 MG | TABLET | APOTEX INC | MARKETED | DIN 02243351 |
| APO-AMOXI CLAV | 875 MG | TABLET | APOTEX INC | MARKETED | DIN 02245623 |
Who else supplies AMOXICILLIN AND BETA-LACTAMASE INHIBITOR worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. AMOXICILLIN AND BETA-LACTAMASE INHIBITOR appears in 3391 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does AMOXICILLIN AND BETA-LACTAMASE INHIBITOR cost around the world?
AMOXICILLIN AND BETA-LACTAMASE INHIBITOR is listed on 15 national price registers Nexara tracks, across 800 pack listings published on 14 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Saudi Arabia | public | 153 | 166 | 01 Sep 2026 |
| Australia | ex-manufacturer | 34 | 132 | 08 Sep 2026 |
| South Africa | single exit price | 96 | 122 | 01 Sep 2026 |
| United States | acquisition | 10 | 98 | 03 Sep 2026 |
| Bahrain | retail (max) | 36 | 93 | 01 Sep 2026 |
| Czechia | max producer price (ex-factory) | 15 | 41 | 03 Sep 2026 |
| Romania | max producer price | 25 | 41 | 03 Sep 2026 |
| Sweden | AIP (pharmacy purchase price) | 14 | 38 | 03 Sep 2026 |
| Austria | KVP (Kassenverkaufspreis) | 18 | 32 | 03 Sep 2026 |
| United Kingdom | hospital | 15 | 15 | 31 Aug 2026 |
| Luxembourg | reimbursement | 9 | 9 | 05 Sep 2026 |
| Iceland | max wholesale | 3 | 5 | 02 Sep 2026 |
| Greece | producer price (ex-factory) | 4 | 4 | 03 Sep 2026 |
| Hungary | producer price (ex-factory) | 3 | 3 | 03 Sep 2026 |
| Lebanon | public price (USD, Decision 119/1) | 1 | 1 | 02 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.